Related Experiment Video
Updated: Jun 5, 2026

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
Published on: February 3, 2021
Intramyocardial adrenergic activation in chagasic cardiomyopathy and coronary artery disease
Luciano Nastari1, Felix Jose Alvarez Ramires, Vera Maria Cury Salemi
1Instituto do Coração, Faculdade de Medicina, Universidade de São Paulo, Rua Doutor Diogo de Faria 1077-62, Vila Clementino, São Paulo-SP, Brazil. lnastari@cardiol.br
Insights
Early cardiac denervation occurs in Chagas' cardiomyopathy (CC) patients with normal ejection fraction, indicated by altered myocardial norepinephrine levels. This finding suggests a distinct pathological pathway compared to coronary artery disease.
Area of Science:
- Cardiology
- Neurocardiology
- Biochemistry
Background:
- Myocardial norepinephrine alterations are linked to left ventricular impairment.
- This relationship remains unexamined in Chagas' cardiomyopathy (CC).
Purpose of the Study:
- To quantify myocardial norepinephrine in CC patients.
- To compare these levels with coronary artery disease (CAD) patients.
- To correlate myocardial norepinephrine with left ventricular ejection fraction (LVEF).
Main Methods:
- Studied 39 CC patients (normal/decreased LVEF) and 17 CAD patients (normal/decreased LVEF).
- Assessed LVEF using two-dimensional echocardiography.
- Measured myocardial norepinephrine via high-performance liquid chromatography.
Main Results:
- CC patients with normal LVEF had significantly lower myocardial norepinephrine (1.3±1.3 pg/μg) than those with dysfunction (6.1±4.2 pg/μg).
- CAD patients showed similar trends (normal LVEF: 3.3±3.0 pg/μg; dysfunction: 9.8±4.2 pg/μg).
- Positive correlation between LVEF and myocardial norepinephrine in both CC (r=0.57) and CAD (r=0.69) patients.
Conclusions:
- Early cardiac denervation is present in CC patients with normal LVEF compared to CAD patients.
- This suggests a unique early-stage pathology in Chagas' cardiomyopathy.
- Myocardial norepinephrine levels are significantly altered in CC, even with preserved ejection fraction.
Background:
Myocardial norepinephrine is altered in left ventricular impairment. In patients with Chagas' cardiomyopathy (CC), this issue has not been addressed.
Objective:
To determine the level of myocardial norepinephrine in patients with CC and compare it in patients with coronary artery disease, and to relate myocardial norepinephrine to left ventricular ejection fraction (LVEF).
Methods:
We studied 39 patients with CC, divided into group 1: 21 individuals with normal LVEF and group 2: 18 individuals with decreased LVEF. Seventeen patients with coronary artery disease were divided into group 3: 12 individuals with normal LVEF and group 4: 5 individuals with decreased LVEF. Two-dimensional echocardiography was used to measure LVEF. Myocardial norepinephrine was determined by high-performance liquid chromatography.
Results:
Myocardial norepinephrine in CC with and without ventricular dysfunction was 1.3±1.3 and 6.1±4.2 pg/μg noncollagen protein, respectively (p<0.0001); in coronary artery disease with and without ventricular dysfunction, it was 3.3±3.0 and 9.8±4.2 pg/μg noncollagen protein, respectively (p<0.0001). A positive correlation was found between LVEF and myocardial norepinephrine concentration in the patients with Chagas' cardiomyopathy (p<0.01, r = 0.57) and also in those with coronary artery disease (p<0.01, r=0.69). A significant difference was demonstrated between norepinephrine concentrations in patients with normal LVEF (groups 1 and 3; p = 0.0182), but no difference was found in patients with decreased LVEF (groups 2 and 4; p = 0.1467).
Conclusion:
In patients with Chagas' cardiomyopathy and normal global ejection fraction there is an early cardiac denervation, when compared to coronary artery disease patients.
Related Concept Videos
Myocarditis I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification

